These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 23516253

  • 21. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
    Wu L, Arevalo JF, Hernandez-Bogantes E, Regatieri CV, Roca JA, Farah ME.
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
    [Abstract] [Full Text] [Related]

  • 22. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
    Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA.
    Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
    [Abstract] [Full Text] [Related]

  • 23. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
    Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, Bandello F.
    Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
    [Abstract] [Full Text] [Related]

  • 24. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
    Amaro MH, Roller AB.
    Arq Bras Oftalmol; 2012 May; 75(4):273-6. PubMed ID: 23258660
    [Abstract] [Full Text] [Related]

  • 25. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 May; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 26. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 27. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S.
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [Abstract] [Full Text] [Related]

  • 28. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D, Sarao V, Lanzetta P.
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [Abstract] [Full Text] [Related]

  • 33. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK, Ozdemir O, Coban DT, Ceran BB, Bulut M.
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [Abstract] [Full Text] [Related]

  • 36. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Mar; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 37. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH, Kim JH, Chang YS, Lee TG, Kim JW, Lew YJ.
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [Abstract] [Full Text] [Related]

  • 38. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K, Pedersen TR, Sandvik L, Bragadóttir R.
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.